These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29021458)

  • 1. Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections.
    Tsukagoshi S; Ishizawa K; Hirayanagi K; Nagamine S; Makioka K; Fujita Y; Ikeda Y
    Intern Med; 2017 Dec; 56(23):3189-3192. PubMed ID: 29021458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis.
    Murata S; Aomatsu T; Yoden A; Tamai H
    Pediatr Int; 2015 Oct; 57(5):942-6. PubMed ID: 25907455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Ceftriaxone-Associated Pseudolithiasis in Adults.
    Matsumi A; Tomoda T; Terasawa H; Fujii Y; Yamazaki T; Uchida D; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H
    Digestion; 2023; 104(4):313-319. PubMed ID: 36907172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: A prospective study in 154 children.
    Ustyol L; Bulut MD; Agengin K; Bala KA; Yavuz A; Bora A; Demiroren K; Dogan M
    Hum Exp Toxicol; 2017 Jun; 36(6):547-553. PubMed ID: 27402682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone-associated Pseudolithiasis in Elderly People: Frequency and Risk Factors.
    Hotta K; Hashimura N; Takatsuka M; Matsuyama T; Nakagawa K; Yabusako T; Hosomi S; Fujiwara Y
    Intern Med; 2021; 60(24):3857-3864. PubMed ID: 34911872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults.
    Yoshida R; Yoshizako T; Katsube T; Kitagaki H
    Jpn J Radiol; 2019 Dec; 37(12):826-831. PubMed ID: 31654330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of ceftriaxone-associated pseudolithiasis in an adult patient that disappeared after the discontinuation of ceftriaxone].
    Tomoda T; Ueki T; Saito S; Tatsukawa M; Nawa T; Hamamoto H; Endo H; Yabushita K; Shimoe T; Sakaguchi K
    Nihon Shokakibyo Gakkai Zasshi; 2013 Aug; 110(8):1481-6. PubMed ID: 23912008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftriaxone-associated Biliary Pseudolithiasis with Elderly Type 1 Diabetes Mellitus: Two Case Reports.
    Kanazawa K; Suzuki S; Inaba T; Koga S; Kuwabara K
    Intern Med; 2023 Nov; 62(22):3367-3371. PubMed ID: 37032086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.
    Imafuku A; Sawa N; Sekine A; Kawada M; Hiramatsu R; Yamanouchi M; Hasegawa E; Hayami N; Hoshino J; Ubara Y; Takaichi K
    Clin Exp Nephrol; 2018 Jun; 22(3):613-619. PubMed ID: 29027036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudden-onset gallbladder rupture due to Ceftriaxone-associated pseudolithiasis in a patient with acquired hemophilia A.
    Harada N; Shibano I; Mukai D; Kizawa Y; Shiragami H; Takayanagi S; Hosaka N; Mugitani A; Hino M
    J Infect Chemother; 2023 Aug; 29(8):796-799. PubMed ID: 37075980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis.
    de Moor RA; Egberts AC; Schröder CH
    Eur J Pediatr; 1999 Dec; 158(12):975-7. PubMed ID: 10592073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis.
    Shima A; Suehiro T; Takii M; Soeda H; Hirakawa M
    Case Rep Nephrol Dial; 2015; 5(3):187-91. PubMed ID: 26558252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical studies on ceftriaxone in respiratory tract infections. CTRX Study Group].
    Shimada K; Kimura H; Kudoh S; Mohri M; Shiraishi T; Amano Y; Kurashima A; Uzawa T; Hisada T; Nagata T
    Jpn J Antibiot; 1993 Feb; 46(2):184-91. PubMed ID: 8331779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child.
    Prince JS; Senac MO
    Pediatr Radiol; 2003 Sep; 33(9):648-51. PubMed ID: 12830336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of Endoscopic Managements in Patients with Ceftriaxone-Induced Pseudolithiasis Causing Biliary Obstruction.
    Doi Y; Takii Y; Ito H; Jingu N; To K; Kimura S; Kimura K; Sanefuji K; Ikeda H; Tachibana S; Otsuka T
    Case Rep Med; 2017; 2017():3835825. PubMed ID: 29230246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reversible ceftriaxone-associated biliary pseudolithiasis in three children with renal diseases].
    Zhong XH; Chen H; Yao Y; Zhuo XW; Huang JP; Xiao HJ; Ai Y
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):216-9. PubMed ID: 20426960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of ceftriaxone in the treatment of neonatal infections].
    Okura K; Yamamoto H; Yamaoka K; Kubo K; Mitsuyoshi I; Haruta T; Kobayashi Y
    Jpn J Antibiot; 1988 Feb; 41(2):152-64. PubMed ID: 3286924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Single-daily-dose treatment of ceftriaxone for biliary tract infections and bacterial counts in bile].
    Tanimura H; Maniwa Y; Okamoto M; Mukaihara S; Takabayashi A; Sato T; Henmi K; Yoshida K; Sawada H
    Nihon Geka Hokan; 1989 May; 58(3):299-309. PubMed ID: 2619435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic and clinical evaluations of ceftriaxone in neonates and premature infants].
    Motohiro T; Oda K; Aramaki M; Tanaka K; Kawakami A; Shimada Y; Koga T; Tomita S; Sakata Y; Fujimoto T
    Jpn J Antibiot; 1988 Mar; 41(3):276-305. PubMed ID: 3404647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment of intra-abdominal infections.
    Starakis I; Karravias D; Asimakopoulos C; Kolaras P; Nikolaidis P; Harlaftis N; Skoutelis A; Bassaris H
    Int J Antimicrob Agents; 2003 Jan; 21(1):49-57. PubMed ID: 12507837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.